Person:
GÜRSU, MELTEM

Profile Picture
Google ScholarScopusORCIDPublons
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
MELTEM
Last Name
GÜRSU
Name
Email Address
Birth Date

Filters

2020 - 20222
Reset filters

Settings

Has files: true × Subject: COVID-19 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    COVİD-19 infection in a membranous nephropathy patient treated with rituximab.
    (2020-09-04T00:00:00Z) Elcioglu, Omer Celal; Artan, Ayse Serra; Mirioglu, Safak; Gursu, Meltem; Durdu, Bulent; Koc, Meliha Meric; Okyaltirik, Fatmanur; Gultekin, Mehmet Ali; Kazancioglu, Rümeyza; ELÇİOĞLU, ÖMER CELAL; MİRİOĞLU, ŞAFAK; GÜRSU, MELTEM; DURDU, BÜLENT; MERİÇ KOÇ, MELİHA; OKYALTIRIK, FATMANUR; GÜLTEKİN, MEHMET ALİ; KAZANCIOĞLU, RÜMEYZA
    While COVID-19 pandemic continues to afect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.
  • Thumbnail Image
    PublicationOpen Access
    Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey
    (2022-05-01T00:00:00Z) ÖZTÜRK, Savaş; Gursu, Meltem; Arici, Mustafa; Sahin, Idris; Eren, Necmi; Yilmaz, Murvet; Ozberk, Sumeyra; Sirali, Semahat Karahisar; Ural, Zeynep; Dursun, Belda; Yuksel, Enver; Uzun, Sami; Sipahi, Savas; Dal, Elbis Ahbap; Yazici, Halil; Altunoren, Orcun; Tunca, Onur; Ayar, Yavuz; Oguz, Ebru Gok; Yilmaz, Zulfikar; Kahvecioglu, Serdar; Asicioglu, Ebru; Oruc, Aysegul; Ataman, Rezzan; Aydin, Zeki; Huddam, Bulent; Dolarslan, Murside Esra; Azak, Alper; Bakirdogen, Serkan; Yalcin, Ahmet Ugur; Karadag, Serhat; Ulu, Memnune Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan; GÜRSU, MELTEM
    Introduction: There are not enough data on the post-CO-VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. Methods: This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. Results: A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88-6.0] years and 3.0 [2.0-5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40-57] years and 56 [IQR: 46-64] years, p < 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. Conclusion: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia.